Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of US$ 117.4 million.
Mr. George Lin, a healthcare veteran brings with him over 20 years of investment banking and legal experience working with numerous private and public companies globally.
Hua Medicine, a leading clinical stage biotech company in Shanghai, announced today positive results in the first-ever successful Phase 2 monotherapy trial of a novel drug class called glucokinase activators (GKA).
The Phase II clinical trial was initiated exactly one year ago on September 22, 2015 with 258 Chinese Type 2 Diabetes patients participating in the drug treatment study.
"Hua Medicine is one of the most innovative healthcare companies in Asia. It has the first new biological mechanism, first-in-class diabetes drug to be developed entirely in China – from preclinical to late-stage clinical trials.
Hua Medicine announced today its third successful clinical trial of lead program HMS5552, a novel glucokinase activator (GKA) treatment for Type 2 diabetes (T2DM).
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号